Hypertonic Saline Inhalation for Mycobacterium Avium Complex Pulmonary Disease
- Conditions
- Nontuberculous Mycobacterial Lung DiseaseMycobacterium Avium Complex
- Interventions
- Device: Hypertonic Saline inhalation
- Registration Number
- NCT05192057
- Lead Sponsor
- Radboud University Medical Center
- Brief Summary
The SALINE trial will investigate the effect of Hypertonic Saline inhalation plus best supportive care on burden of symptoms, clearance of mycobacteria and functional capacities in participants with Mycobacterium avium complex lung disease and compare the effect to treatment with best supportive care alone.
- Detailed Description
The treatment of Mycobacterium avium complex (MAC) lung disease consists of best supportive care, often accompanied by long-lasting multi-drug antibiotic regimens. Two major radiologic patterns exist: nodular-bronchiectatic and fibrocavitary disease, characterized by slow and rapid progression of disease, respectively.
SALINE is an open-label, randomized, two-arm controlled study that investigates the effect of Hypertonic Saline inhalation (HSi) plus best supportive care versus best supportive care alone for 12 weeks in participants with nodular-bronchiectatic MAC lung disease. The investigators hypothesize that HSi added to best supportive care will improve health-related quality of life and reduce mycobacterial load more than best supportive care alone Participants will be randomized 1:1 to a study arm. Best supportive care comprises of management of a predisposing (lung) condition, guidance in smoking cessation, respiratory physiotherapy (e.g. airway clearance) and nutritional guidance. HSi will be administered two times daily. Antibacterial therapy against other bacterial infections and inhaled corticosteroids are allowed during the study period.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
- International guideline criteria for nodular-bronchiectatic MAC lung disease, i.e. symptomatic, nodular bronchiectatic lesions seen on thorax radiography and ≥2 positive cultures of the same MAC species or one positive culture from a bronchoalveolar lavage;
- ≥1 positive MAC sputum cultures must be collected in the previous 4 months;
- Signed and dated patient informed consent.
- Fibrocavitary MAC lung disease;
- Antimycobacterial treatment in the last 6 months;
- Previous MAC lung disease treatment failure, defined as persistent culture positivity despite >6 months of guideline-recommended treatment;
- Current clinical relevant asthma or otherwise bronchial hyperresponsiveness that is judged to be a contra-indication for HSi.
- Current HSi use
- Former adverse reaction to HSi (note: former HSi use that was stopped due to a lack of clinical improvement is not an exclusion criterium);
- Hypertonic saline intolerability during the screening test inhalation
- Diagnosis of HIV;
- Diagnosis of Cystic fibrosis (CF);
- Active pulmonary malignancy (primary or metastatic) or any other malignancy requiring chemotherapy or radiotherapy within 6 months before screening or anticipated during the study period;
- Active pulmonary tuberculosis, fungal or nocardial disease requiring treatment
- Current use of chronic systemic corticosteroids at doses of 15 mg/day for more than 3 months
- Prior lung or other solid organ transplant
- Known or suspected current drug or alcohol abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the patient.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Hypertonic Saline inhalation Hypertonic Saline inhalation Participants randomized to the Hypertonic Saline inhalation arm will be prescribed a nebulizer for Hypertonic Saline Inhalation (5ml, 5.8%) two times a day for 12 weeks. Participants will also receive best supportive care for 12 weeks (see below).
- Primary Outcome Measures
Name Time Method Change in health-related quality of life 12 weeks Measured by the PROMIS Fatigue 7a short form at baseline, after 4, 8 and 12 weeks. This questionnaire assesses self-reported fatigue over the past seven days on a 5 scale base ranging from never (1) to always (5). The lowest possible raw score (indicating the highest subjective level of fatigue) is 7; and the highest possible raw score (indicating the lowest subjective level of fatigue) is 35.
- Secondary Outcome Measures
Name Time Method Change in semi-quantitative culture results 12 weeks Change in sputum culture time-to-positivity
Change in pulmonary function parameters 12 weeks Tiffeneau index (FEV1/FVC; %)
Change in self-reported health status 12 weeks Change in the Nijmegen Clinical Screening Instrument (NCSI) from baseline to 12 weeks. The NCSI evaluates clinical, social and emotional self-reported measures, serves as a tool for an individualized treatment plan and can be repeated regularly to monitor the treatment effect
(Serious) Adverse Events as assessed by CTCAE v5.0 12 weeks Number and severity of (serious) Adverse Events as assessed by CTCAE
Change in physical function capacity 12 weeks Change in 6-Minute Walking Distance (6MWD).
Change in inflammatory serum biomarkers 12 weeks White blood cell count.
Therapy adherence 12 weeks Self-reported therapy adherence expressed as percentage taken of total HSi administrations.
Sputum culture conversion 12 weeks A conversion from positive sputum cultures at baseline to negative sputum cultures after study treatment, defined by two or more negative sputum cultures sampled a week apart.
Treatment failure 12 weeks Progression of disease that requires the start of antimycobacterial treatment as per the treating physician's discretion.
Trial Locations
- Locations (1)
Radboud University Medical Center
🇳🇱Nijmegen, Netherlands